Condition: Kidney Transplant Rejection · Sponsor: Sanofi
The purpose of this open-label, randomized, active-comparator-controlled study is to determine the efficacy and safety of frexalimab subcutaneous administrations up to 5 years compared to tacrolimus capsules in adults undergoing kidney transplantation. Participants aged 18 to 70 years who have low-to-moderate immunologic risk of graft rejection and receive their first kidney transplant are eligible if they meet all inclusion and no exclusion criteria. Study details include: * The study and treatment duration will be up to approximately 5 years. * The number of visits will be approximately 38.
This description comes directly from the study's public registry record.
Trial Transparency email recommended (Toll free for US & Canada) · 800-633-1610 · Contact-US@sanofi.com
Always discuss trial participation with your own doctor first.
| Brigham & Women's Hospital- Site Number : 8400049 | Boston, Massachusetts, United States | Recruiting |
| Montefiore Medical Center - Moses Campus- Site Number : 8400006 | The Bronx, New York, United States | Recruiting |
| Investigational Site Number : 0320001 | Corrientes, Argentina | Recruiting |
| Investigational Site Number : 0360002 | Adelaide, South Australia, Australia | Recruiting |
| Investigational Site Number : 0360001 | Parkville, Victoria, Australia | Recruiting |
| Investigational Site Number : 0360003 | Sydney, Australia | Recruiting |
| Investigational Site Number : 0560002 | Brussels, Belgium | Recruiting |
| Investigational Site Number : 1520005 | Santiago, Reg Metropolitana de Santiago, Chile | Recruiting |
| Investigational Site Number : 1520004 | Santiago, Reg Metropolitana de Santiago, Chile | Recruiting |
| Investigational Site Number : 1560003 | Chengdu, China | Recruiting |
| Investigational Site Number : 1560012 | Jinan, China | Recruiting |
| Investigational Site Number : 1560017 | Nanchang, China | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07412470